European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The RNase activities have been assayed in 1678 serum samples from a total of 209 patients. 52 with histologically confirmed ovarian carcinoma, 13 with benign tumors of the ovary, and 144 patients without any clinically detectable malignancy. The serum RNase activity is unequivocally increased in the group with ovarian cancer (p < 0.01). Considering the distribution of the RNase activities with a margin at 300 ngeqvs/ml serum we find 8.3% false negative and 4.9% false positive results. The serum RNase activity does not display any evident relationship with tumor spread, histology, clinical grading(TNM), nor metastasis at the time of the blood taking. It is conclude that the serum RNase activity is a meaningful criterion together with the careful clinical examination for he diagnosis and the surveillance of ovarian cancer.